Objective: To conduct a systematic review and meta-analysis to evaluate imaging methods used to diagnose adenomyosis. Data Sources: A thorough search was completed through the Cochrane Central Register of Controlled Trials, EMBASE, and PubMed or MEDLINE databases from January 2000 to June 2019. Methods of Study Selection: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Quality Assessment of Diagnostic Accuracy Studies 2 tool, studies reporting the diagnostic accuracy of an imaging method and histopathology as a reference standard were selected and prospectively registered in the International Prospective Register of Systematic Reviews. Statistical analysis was performed using the R-package Meta-Analysis of Diagnostic Accuracy. Tabulation, Integration, and Results: Of the 1168 records identified, 10 studies were included in the meta-analysis, and these included 827 patients undergoing 2-or 3-dimensional transvaginal ultrasound (TVUS) and 317 patients undergoing magnetic resonance imaging (MRI). The risk of bias was low or unclear for all Quality Assessment of Diagnostic Accuracy Studies domains. The overall prevalence of adenomyosis was 40%. Overall MRI, 2-dimensional TVUS, 3-dimensional TVUS, and TVUS had the following aggregated diagnostic qualities (95% confidence interval): sensitivity of 78% (70%−84%), 74% (68%−79%), 84% (77%−89%), 78% (73%−82%); specificity of 88% (83%−92%), 76% (71%−79%), 84% (77%−89%), 78% (74%−81%); positive likelihood ratio of 6.8 (4.5%−10%), 3 (2.5%−3.7%), 5.2 (3.6%−7.4%), 3.5 (3%−4.2%); negative likelihood ratio of 0.25 (0.18%−0.35%), 0.34 (0.27%−0.43%), 0.19 (0.13%−0.28%), 0.28 (0.23%−0.34%); and pooled area under the operator curve of 0.77, 0.7, 0.83, 0.73, respectively. The pooled area under the operator curve for all modalities was not significantly different (all: p ≥.4). Conclusion:As a result of the systemic review and meta-analysis, we identified TVUS and MRI as good and comparable noninvasive imaging methods for diagnosing adenomyosis, leading us to recommend TVUS as the first-line diagnostic imaging method and MRI as a second-line method, if TVUS is inconclusive.

No abstract

No abstract

Antibody levels to VEGFR1, serotonergic receptors, and receptors in the immune system were increased in AD. Antibodies at similar levels as in controls were associated cognitive dysfunction and depression in AD.

Lu-lilotomab satetraxetan is a novel antibody-radionuclide conjugate currently in a phase 1/2a first-in-humans dose escalation trial for patients with relapsed CD37-positive indolent non-Hodgkin lymphoma. The aim of this study was to investigate biodistribution and absorbed doses to organs at risk. In total, 7 patients treated withLu-lilotomab satetraxetan were included for dosimetry. Patients were grouped on the basis of 2 different predosing regimens (with and without predosing with 40 mg of lilotomab) and were treated with different levels of activity per body weight (10, 15, and 20 MBq/kg). All patients were pretreated with rituximab. Serial planar and SPECT/CT images were used to determine time-activity curves and patient-specific masses for organs with Lu-lilotomab satetraxetan uptake. Doses were calculated with OLINDA/EXM. The organs (other than red bone marrow and tumors) with distinct uptake of Lu-lilotomab satetraxetan were the liver, spleen, and kidneys. The highest uptake was found in the spleen, with doses ranging from 1.54 to 3.60 mGy/MBq. The liver received 0.70-1.15 mGy/MBq. The kidneys received the lowest dose of the source organs investigated, 0.16-0.79 mGy/MBq. No statistically significant differences in soft-tissue absorbed doses were found between the two predosing regimens. The whole-body dose ranged from 0.08 to 0.17 mGy/MBq. The biodistribution study for patients treated with Lu-lilotomab satetraxetan revealed the highest physiologic uptake to be in the liver and spleen (besides the red marrow). For all treatment levels investigated, the absorbed doses were found to be modest when compared with commonly assumed tolerance limits.